| Date Filed | Type | Description |
| 03/27/2019 |
GN
| Market Trends Toward New Normal in 3M, Exelixis, Wright Medical Group N.V, MSA Safety Incorporated, Principal Financial Group, and Portland General Electric — Emerging Consolidated Expectations, Analyst Ratings |
| 12/12/2018 |
GN
| Report: Developing Opportunities within Exelixis, Cintas, BGC Partners, FirstEnergy, Hologic, and Trevena — Future Expectations, Projections Moving into 2018 |
| 08/23/2018 |
GN
| Recent Analysis Shows KB Home, Sleep Number, Exelixis, Sprint, PayPal, and Halozyme Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth |
| 05/02/2018 |
BW
| Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update |
| 04/17/2018 |
GN
| New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 04/11/2018 |
BW
| Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018 |
| 02/26/2018 |
BW
| Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update |
| 02/01/2018 |
GN
| Report: Developing Opportunities within Omega Flex, Sun, First Citizens BancShares, Zynga, Infinera, and Exelixis — Future Expectations, Projections Moving into 2018 |
| 01/16/2018 |
BW
| Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma |
| 11/27/2017 |
GN
| Report: Developing Opportunities within PayPal, Exelixis, International Business Machines, Opko Health, Envision Healthcare, and Zynga — Future Expectations, Projections Moving into 2018 |
| 11/21/2017 |
BW
| Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations |
| 11/01/2017 |
BW
| Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update |
| 10/18/2017 |
BW
| Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017 |
| 09/09/2017 |
BW
| Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 |
| 09/06/2017 |
BW
| Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress |
| 08/02/2017 |
BW
| Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update |
| 07/17/2017 |
BW
| Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017 |
| 05/01/2017 |
BW
| Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update |
| 04/24/2017 |
BW
| Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3 |
| 04/18/2017 |
BW
| Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017 |
| 02/27/2017 |
BW
| Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update |
| 02/02/2017 |
BW
| Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017 |
| 07/21/2011 |
BW
| Exelixis Announces August 4th Webcast of Second Quarter 2011 Financial Results Conference Call |
| 07/06/2011 |
BW
| Exelixis Provides Update on Cabozantinib Development Activities |
| 06/06/2011 |
BW
| Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer |
| 06/05/2011 |
BW
| Exelixis' Cabozantinib Demonstrates Broad Clinical Activity in Multiple Tumor Types |
| 06/04/2011 |
BW
| Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity in Patients with Metastatic Ovarian Cancer |
| 06/01/2011 |
BW
| Exelixis Announces Webcasts of June Investor Conference Presentations |
| 05/31/2011 |
BW
| Reminder: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
| 05/23/2011 |
BW
| Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology |
| 05/18/2011 |
BW
| Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer Treatment Advances and ASCO Highlights |
| 05/13/2011 |
BW
| UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
| 05/13/2011 |
BW
| UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
| 05/09/2011 |
BW
| CORRECTING and REPLACING Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
|